August 29, 2022  

Celloram presents its Protexi technology at the 2nd Annual Global NeoAntigen Vaccine Summit in Boston, MA

Dr. Seungwhan Lim, VP and Directior of Scientific Operations, Cell Therapy Division, presented at the Global NeoAntigen Vaccine Summit in Boston, MA on August 17-18, 2022. Also in attendance were industry leaders in the cancer vaccine development space, including Janseen R&D, Moderna and Genetech. The NeoAntigen Vaccine Summit serves as an opportunity for industry experts to trade up-to-date clinical and commercial developments in next-generation cancer vaccine platforms.

Celloram’s Protexi technology is an innovative cancer vaccine that provides personalized cell therapy by helping to activate the patient’s own immune response against cancer cells. Protexi utilizes personalized tumor-specific antigens, called neoantigens, that are created from genomic analyses of the patient’s tumor. These antigens are then loaded into expanded autologous mature dendritic cells to help trigger the patient’s own immune system response against the tumor. Together in combination with immune modulators, Protexi forms the basis of next-generation cancer vaccines designed to target difficult to treat tumors, including therapy-resistant, immune-cold and inoperable tumors for which survival rates remain unacceptably low.    

October 16, 2020  

Celloram successfully closes its 8M Seed Series Round

Celloram successfully closed its $8M Seed Series Round, securing funds to advance its mission of developing safer and more effective treatments for cancer, immune and metabolic disorders. Seed Series investors include MedPacto Inc., Theragen Etex, and Winvest, among others.

Celloram’s research pipelines focus on both innovative cell therapies and novel small molecule therapeutics, with primary indications including difficult-to-treat triple negative breast cancer (TNBC) and graft-versus-host disease (GVHD). The Seed Series funds will allow Celloram to expand its research team and facilities and provide continued support of the development of novel therapies for these critical disease indications.